NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The general objective of the present clinical trial is to compare the therapeutic efficacy of
a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and
hepatitis B core antigen (HBcAg) [later called NASVAC] with a commonly used antiviral drug,
pegylated interferon in patients with chronic hepatitis B (CHB).